





Definitive HNSCC

UCI 22-132

De-escalated Radiation HPV 16+ SCC OPC PI: Dr. Chen Coord: E. Palmer-Torrison Accrual: 22/111

UCI 21-173

AHCC w/ SOC Tx **HPV+ HNSCC** PI: Dr. Nabar Coord: A. Reipolska Mushroom Extract Accrual: 5/34

HN009

Cisplatin Q3 weeks vs Weekly Locally Advanced HNSCC PI: Dr. Attarian Coord: A. Reipolska

Accrual: 1/5 **Temporarily Suspended for data analysis**

Adjuvant

Open to Accrual

EA3132 (TP53)

XRT +/- Cisplatin Adjuvant Dr. Attarian Coord: A. Reipolska Accrual: 0/5

Re-radiation

EA3191

Low Accruing Pending Activation/Suspended

Pembrolizumab Adjuvant Recurrent/2ndary HNSCC Attarian Coord: N. Arechiga Accrual: 0/5



Open to Accrual Low Accruing Pending Activation/Suspended

1st Line Recurrent/Metastatic HNSCC

<u>UCI 24-130</u>

HPV injection + Pembro 1st line Recurrent/Metastatic HPV+ Pl: Attarian Coord: Anastasiia R. Accrual: 0/5

RTOG 3521

Gem+Cis+ Tori 1st line Recurrent/Metastatic NPC PI: Attarian Coord: N. Arechiga Accrual: 1/5

Recurrent/Metastatic

UCI 25-49

Petosemtamab vs Phys Choice Recurrent HNSCC PI: Attarian CRC: TBD Accrual: TBD

Alliance A092105

2nd line Ipi/Nivo +/- Cabozantinib Recurrent NPC PI: Attarian Coord: B. Huynh Accrual: 0/5

<u>**S2101**</u> Nivo + Cabozantinib

HNSCC, Melanoma PI: Dr. Vaidya Coord: Natalie A Accrual: 0/5

ETCTN 10553

Darolutamide + Leuprolide Acetate in Hormone Naïve AR+ Salivary Gland Cancer Pl: Attarian Coord: B. Huynh Accrual: 2/5

EA3231

BRAF Agent vs Cabozantinib Recurrent Thyroid Cancer PI: Attarian Coord: E. Palmer-Torrison Accrual: 0/5



Broad Phase 1 Trials

UCI 25-106

IP Monotherapy HNSCC, 2L+ sq/nsq NSCLC, TNBC PI: Dr. Nabar

> Coord: TBD Accrual: TBD

UCI 25-170

Immunogenesis HNSCC, 2L+ sq/nsq NSCLC, TNBC

Dr. Villaflor Coord: TBD Accrual: 0/5

UCI 22-09

B7-H4-targeted antibody-drug conjugate PI: Dr. Parajuli CRC: N. Arechiga Accrual: 6/10

Waitlist only

UCI 24-113

BMS

HNSCC, Melanoma, NSCLC, TNBC

PI: Dr. Chow Coord: Natalie A. Accrual: 0/5

